Graduation Year
2020
Document Type
Master's Thesis
Degree
Master of Science
Program
Biological Science
Program Director
Meredith Protas, PhD
First Reader
Lisa M. Ellerby, PhD
Second Reader
Kiowa Bower, PhD
Abstract
Huntington’s disease (HD) is a rare and incurable autosomal neurodegenerative disease affecting 1-10 in every 100,000 people in the world. There is no cure for HD and treatments available alleviate certain symptoms for short periods of time. Evidence suggests that neuropathology of HD begins with the proteolysis of the mutated Huntingtin (mHTT) protein. A variety of proteases, like the matrix metalloproteases, cleave mHTT creating proteinaceous fragments that are thought to be neurotoxic. As these fragments increase in the brain, the damage to neurons also increases, leading to chronic inflammation due to hyper reactive microglia and astrocytes attempting to minimize and repair damages. There are many potential avenues to treat HD and, in this study, we provide insight on regulating proteolytic dysfunction with the systemic introduction of endogenous tissue inhibitor for metalloproteases-2 (TIMP2). In addition, we suppress inflammation in a selective manner with compound MW151 in order to attenuate the increasing levels of pro-inflammatory markers and reactive gliosis in HD.
Included in
Biochemistry Commons, Immunity Commons, Medicine and Health Sciences Commons, Molecular and Cellular Neuroscience Commons, Molecular Biology Commons